Webinar - Clinical trials targeting alpha-synuclein
At this webinar, Professor Tilo Kunath of Edinburgh University is joined by a panel of experts in the field of alpha-synuclein research, answering questions such as:
What is alpha-syunclein, what does it do, and why does it aggregate in Parkinson’s?
Are there different types of alpha-synuclein?
Is alpha-synuclein the right target in seeking to slow the progression of Parkinson’s?
What does the clinical trials landscape look like for targeting alpha-synuclein?
Joining Professor Kunath is: Gennaro Pagano, Expert Medical Director & Group Leader from Roche Pharma Research, Carroll Siu, person living with Parkinson’s and advisor to biopharmaceutical company UCB, on clinical outcomes; and Hilal Lashuel, Associate Professor of Life Sciences and Director of the Laboratory of Chemical Biology of Neurodegeneration, Brain Mind Institute.